Skip to main content
SpringerLink
Log in

Statins and Ezetimibe

  • Chapter
Combination Therapy In Dyslipidemia

Abstract

In 1929, Schoenheimer reported that mammals not only synthesize cholesterol de novo but also absorb dietary cholesterol from the intestine while excluding dietary plant sterols [1]. Both dietary cholesterol consumption and intestinal cholesterol absorption contribute to plasma cholesterol concentrations. Ezetimibe lowers plasma cholesterol by decreasing cholesterol absorption in the small intestine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schoenheimer R. Über die Bedeutung der Pflanzensterine für den tierischen Organismus. Z Phys Chem. 1929;180:1.

    Article  Google Scholar 

  2. Altmann SW, Davis Jr HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201–4.

    Article  CAS  PubMed  Google Scholar 

  3. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415–27.

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106(15):1943–8.

    Article  CAS  PubMed  Google Scholar 

  5. Salen G, von Bergmann K, Kwiterovitch P, et al. Ezetimibe is an effective treatment for homozygous sitosterolemia. Circulation. 2002;106(suppl II):II–185. Abstract.

    Google Scholar 

  6. Sudhop T, von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs. 2002;62(16):2333–47.

    Article  CAS  PubMed  Google Scholar 

  7. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation. 2003;107(25):3124–8.

    Article  PubMed  Google Scholar 

  8. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572–80.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Klose G, Laufs U, März W, Windler E. Familial hypercholesterolemia: developments in diagnosis and treatment. Dtsch Arztebl Int. 2014;111(31–32):523–9.

    PubMed Central  PubMed  Google Scholar 

  10. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631–9.

    Article  CAS  PubMed  Google Scholar 

  11. Ference BA. Effect of naturally random allocation to lower LDL-C mediated by polymorphisms in NPC1L1, HMGCR or both on the risk of coronary heart disease: a 2x2 Factorial Mendelian Randomization Study. American Heart Association Scientific Sessions, Chicago; 16 Nov 2015 2014.

    Google Scholar 

  12. Stitziel NO, Won HH, Morrison AC, Peloso GM, Do R, et al. Myocardial Infarction Genetics Consortium I Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371(22):2072–82.

    Article  PubMed  Google Scholar 

  13. Weingärtner O, Lütjohann D, Ji S, Weisshoff N, List F, Sudhop T, et al. Vascular effects of diet supplementation with plant sterols. J Am Coll Cardiol. 2008;51(16):1553–61.

    Article  PubMed  Google Scholar 

  14. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107(19):2409–15.

    Article  CAS  PubMed  Google Scholar 

  15. Leiter LA, Bays H, Conard S, Bird S, Rubino J, Hanson ME, et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol. 2008;102(11):1495–501.

    Article  CAS  PubMed  Google Scholar 

  16. Reckless JP, Henry P, Pomykaj T, Lim ST, Massaad R, Vandormael K, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract. 2008;62(4):539–54.

    Article  CAS  PubMed  Google Scholar 

  17. Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract. 2009;63(4):547–59.

    Article  CAS  PubMed  Google Scholar 

  18. Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol. 2008;102(11):1489–94.

    Article  CAS  PubMed  Google Scholar 

  19. Hurley DL, Isley WL. Getting there: statin plus ezetimibe for low-density lipoprotein cholesterol goals. Mayo Clin Proc. 2005;80(5):587–95.

    Google Scholar 

  20. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431–43.

    Article  CAS  PubMed  Google Scholar 

  21. Fleg JL, Mete M, Howard BV, Umans JG, Roman MJ, Ratner RE, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008;52(25):2198–205.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343–56.

    Article  PubMed  Google Scholar 

  23. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Cannon CP. IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. American Heart Association Scientific Sessions, Chicago; 17 Nov 2014; Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015. doi:10.1056/NEJMoa1410489.

  25. Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA, et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014;168(2):205–12.e1.

    Article  CAS  PubMed  Google Scholar 

  26. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156(5):826–32.

    Article  CAS  PubMed  Google Scholar 

  27. Packard CJ. Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year followup of the West of Scotland coronary prevention study. American Heart Association Scientific Sessions, Chicago; 18 Nov 2014 2014.

    Google Scholar 

  28. Urban D, Pöss J, Böhm M, Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62(16):1401–8.

    Article  CAS  PubMed  Google Scholar 

  29. Schulz R, Schlüter KD, Laufs U. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol. 2015;110(2):463.

    Article  Google Scholar 

  30. Lipka L, Kerzner B, Corbelli J. Results of ezetimibe coadministered with lovastatin in 548 patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;39(9 suppl B):430B.

    Google Scholar 

  31. Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeaut A, et al. Ezetimibe co-administered with pravastatin in 538 patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;39(9 suppl B):134B.

    Google Scholar 

  32. Davidson M, McGarry T, Bettis R, et al. Ezetimibe Study Group. Ezetimibe co-administered with simvastatin in 668 patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;39(Suppl A):226A–227A.

    Google Scholar 

  33. Ballantyne C, Houri J, Notarbatolo A, et al. Ezetimibe Study Group. Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;39(Suppl A):227A.

    Google Scholar 

  34. Ballantyne CM, Lipka LJ, Sager PT, Strony J, Alizadeh J, Suresh R, Veltri EP. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract. 2004;58(7):653–8.

    Article  CAS  PubMed  Google Scholar 

  35. Laufs U, Descamps OS, Catapano AL, Packard CJ. Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. Eur Heart J. 2014;35(30):1996–2000.

    Google Scholar 

Download references

Acknowledgments

The authors are indebted to Anja Zickwolf (Homburg/Saar, Germany) for technical assistance.

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar, 66421, Germany

    Ulrich Laufs

Authors
  1. Ulrich Laufs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Laufs .

Editor information

Editors and Affiliations

  1. Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Lodz, Poland

    Maciej Banach

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Laufs, U. (2015). Statins and Ezetimibe. In: Banach, M. (eds) Combination Therapy In Dyslipidemia. Adis, Cham. https://doi.org/10.1007/978-3-319-20433-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20433-8_3

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-20432-1

  • Online ISBN: 978-3-319-20433-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation